Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
For adults, a maximum dose of 266 mg (20 mL) is recommended, based on:
For pediatric patients aged 6 to less than 17 years, dosing is weight based: 4 mg/kg (up to a maximum of 266 mg)
See how your peers are using EXPAREL for optimal pain coverage
EXPAREL is a cost-effective option for postsurgical pain management both in the hospital and in outpatient settings
Medical center in Florida
2.7 days shorter length of stay
$3,444 reduction in total cost for acute-care hospitalization*
100% rate of discharge home
Medical center in Massachusetts
Significantly better pain control reported in the first 24 hoursâ€
34% fewer opioids used at 12 to 24 hours‡§
1.2 days shorter LOS
$590 lower mean total per-patient cost
*Areas of greatest savings included a reduction in intensive care unit costs, shorter overall LOS, and decreased costs from a reduced operating room duration.1
†Pain was self-reported by patients using the visual analog scale. Scores recorded over the first 3 days were divided into 12-hour intervals and used to calculate the area under the curve.2
‡Opioid consumption was measured using intravenous morphine milligram equivalent.2
§The clinical benefit of the decrease in opioid consumption was not demonstrated in the clinical trials.
LOS, length of stay; TLIF transforaminal lumbar interbody fusion.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.